Loading
The molecular landscape: the targets and how often each appears, the pathways, the mechanics stages and the preclinical models.
The targets of this cancer's medicines and the ones linked to it directly.
| Target / alteration | Prevalence | Measure | Source |
|---|---|---|---|
| TP53 RB1 co-loss | >90% | TP53 mutation | Wikipedia |
| TP53 cBioPortal: 103 of 120, 85.8%, carry a non-synonymous TP53 mutation in sclc_ucologne_2015. Whole-genome sequencing of 110 small-cell lung cancers found biallelic inactivation of TP53 in nearly all tumours, sometimes through complex genomic rearrangement rather than point mutation, which is why a mutation call alone reads lower (George 2015). | 86-100% | Biallelic inactivation | cBioPortal (TCGA) |
| RB1 cBioPortal: 87 of 120, 72.5%, carry a non-synonymous RB1 mutation in sclc_ucologne_2015, against 34 of 566, 6.0%, in lung adenocarcinoma. Biallelic inactivation was found in nearly all of the 110 sequenced genomes, and the two tumours with wild-type RB1 showed chromothripsis leading to cyclin D1 overexpression, an alternative route to the same deregulation (George 2015). | 73-100% | Biallelic inactivation | cBioPortal (TCGA) |
| DLL3 | 80-85% | IHC, any expression | Wikipedia |
| B7-H3 | 60-70% | IHC, any expression | Wikipedia |
| Somatostatin receptor 2 | 30-50% | IHC/imaging | Wikipedia |
| NOTCH1 cBioPortal: NOTCH1 mutated in 16 of 120, 13.3%, in sclc_ucologne_2015. Inactivating mutations across the NOTCH family were found in 25% of the sequenced tumours, and activating Notch signalling in a mouse model strikingly reduced tumour number, extended survival and abolished neuroendocrine gene expression (George 2015). | 13-25% | Inactivating mutation | cBioPortal (TCGA) |
| PD-L1 | 15-20% | Any tumour-cell expression | Wikipedia |
How common each drug target or alteration is in this cancer. Population-level and approximate; see the target page for detail. Full matrix.
4 cell lines, 2 mouse models and 6 repositories are listed for this cancer. See them →